Asymchem has welcomed Dr. Cheng Yi Chen as CTO of the Small-Molecule Sector. He will report directly to Asymchem’s CEO, Dr. Hao Hong.

In this position, Chen will provide technical support to the group’s chemical small molecule sales in the European and United States markets. His main duties include active participation in technical communications for key mid-to-late-stage clinical projects in Europe and United States and facilitating collaborations with crucial new clients by capitalizing on the overall technical capabilities of the group’s chemical small-molecule sector.

He will also offer guidance to the China Core Team on project-related technical matters with European and United States clientele and provide advisory input for communication. Additionally, he will provide technical expertise suggestions for the Boston site in the United States, as well as supervising technical operations at small-molecule laboratories and pilot production sites across Europe.

Prior to joining Asymchem, Chen worked at Merck Research Laboratories, Janssen Pharmaceuticals of Johnson & Johnson, Mirati Therapeutics, and Bristol Myers Squibb. He has extensive experience designing, developing, and implementing robust, cost-effective, and green manufacturing routes for small molecule APIs, ensuring CMC compliance and quality, collaborating with cross-functional drug development teams and external partners, and supporting regulatory filings.

Chen received his Ph.D. in organic chemistry from The Ohio State University.